MCID: ESS003
MIFTS: 66

Essential Thrombocythemia malady

Genetic diseases, Rare diseases, Blood diseases, Cancer diseases categories

Aliases & Classifications for Essential Thrombocythemia

About this section
Sources:
41NIH Rare Diseases, 21Genetics Home Reference, 43Novoseek, 47Orphanet, 22GTR, 60UMLS, 34MESH via Orphanet, 26ICD10 via Orphanet, 61UMLS via Orphanet
See all sources

Essential Thrombocythemia, Aliases & Descriptions:

Name: Essential Thrombocythemia 41 21 47
Essential Thrombocytosis 41 21 47
Thrombocythemia Essential 43 22
Primary Thrombocythemia 41 21
Et 41 47
 
Hemorrhagic Thrombocythemia 41
Idiopathic Thrombocythemia 41
Thrombocythemia, Essential 60
Primary Thrombocytosis 21


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Genetic diseases, Rare diseases, Cancer diseases
Anatomical: Blood diseases


Characteristics (Orphanet epidemiological data):

47
essential thrombocythemia:
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (United States),1-5/10000 (Sweden); Age of onset: All ages; Age of death: normal life expectancy


External Ids:

Orphanet47 3318
MESH via Orphanet34 D013920
ICD10 via Orphanet26 D47.3
UMLS via Orphanet61 C0040028

Summaries for Essential Thrombocythemia

About this section


NIH Rare Diseases:41 Essential thrombocythemia belongs to a group of conditions called myeloproliferative disorders. myeloproliferative disorders cause platelets, white blood cells and red blood cells to grow abnormally in the bone marrow (the soft tissue inside the hollow part of bones that helps form blood cells). in essential thrombocythemia, the body produces too many platelet cells. the signs and symptoms vary from person to person, with up to two-thirds of patients not having any symptoms when the platelet cell count first increases. signs and symptoms may include significant increased production of megakaryocyte (a cell in the bone marrow that is responsible for making platelets), enlargement of the spleen (splenomegaly), and bleeding and/or clotting episodes. last updated: 6/30/2011

MalaCards based summary: Essential Thrombocythemia, also known as essential thrombocytosis, is related to myelofibrosis and polycythemia, and has symptoms including coronary artery disease, abnormality of thrombocytes and abnormality of coagulation. An important gene associated with Essential Thrombocythemia is THPO (thrombopoietin), and among its related pathways are IL-9 Signaling Pathways and Jak/Stat Pathway. The drugs hydroxyurea and interferon alfa-2a and the compounds megapoietin and anagrelide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and spleen, and related mouse phenotypes are embryogenesis and growth/size/body.

Genetics Home Reference:21 Essential thrombocythemia is a condition characterized by an increased number of platelets (thrombocythemia). Platelets (thrombocytes) are blood cell fragments involved in blood clotting. While some people with this condition have no symptoms, others develop problems associated with the excess platelets.

Related Diseases for Essential Thrombocythemia

About this section

Diseases in the Essential Thrombocythemia family:

Thrombocythemia 2 Thrombocythemia 1
Thrombocythemia 3 Thpo-Related Essential Thrombocythemia

Diseases related to Essential Thrombocythemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 150)
idRelated DiseaseScoreTop Affiliating Genes
1myelofibrosis32.4THPO, JAK2
2polycythemia32.3MPL, CD177, JAK2, THPO, PPBP
3myocardial infarction31.5TPO, SULT1A3, PF4, PPBP
4polycythemia vera31.4MPL, PF4, JAK2, IFNA2, TET2, THPO
5purpura31.3THPO
6myeloma31.2PF4, IGH, JAK2, IFNA2
7erythromelalgia31.2PF4, PPBP, THBD
8refractory anemia31.2MPL, JAK2, THPO
9acute myocardial infarction31.2PPBP, THBD, PF4, SULT1A3
10chronic lymphocytic leukemia31.0THPO, IGH, JAK2
11myelodysplastic syndrome31.0CD177, MPL, THPO, JAK2
12thrombophilia30.9PPBP, PF4, THBD
13systemic mastocytosis30.9IFNA2, JAK2
14chronic myeloproliferative disease30.9JAK2, MPL, THPO
15sarcoma30.9TP53, JAK2, THPO, TPO
16thrombocytosis30.8IFNA2, PPBP, TET2, THPO, THBD, JAK2
17megakaryocytic leukemia30.8PF4, THPO
18splenomegaly30.8IFNA2, THPO, MPL, JAK2
19acute leukemia30.7MPL, JAK2, IGH, THPO
20thrombocythemia 130.6SH2B3, CALR
21leukemia30.5MPL, PPBP, TET2, THPO, IGH, TP53
22chronic myelomonocytic leukemia30.4MPL, JAK2
23thrombocytopenia30.4ALOX12, THBD, PF4, PPBP, MPL, IFNA2
24atherosclerosis30.1THBD, KLF5, TPO, SULT1A3, PPBP, PF4
25rheumatoid arthritis30.0JAK2, CALR, ALOX12, PF4, THPO, PPBP
26cerebritis10.6
27myeloid leukemia10.6
28endotheliitis10.6
29multiple myeloma10.5
30peripheral vascular disease10.5PPBP
31thrombocytopenia, congenital amegakaryocytic10.5MPL, THPO
32thrombocytopenia due to platelet alloimmunization10.5THPO, MPL
33bone marrow cancer10.5MPL, JAK2
34severe congenital neutropenia10.5JAK2, THPO
35mitral valve stenosis10.5PF4, PPBP
36thrombocytopenic purpura, autoimmune10.5IFNA2, THPO, MPL
37inherited predisposition to essential thrombocythemia10.4
38hematologic cancer10.4JAK2, MPL, THPO
39neutropenia10.4CD177, IFNA2, MPL, THPO
40pancytopenia10.4MPL, THPO
41budd-chiari syndrome10.4
42acute biphenotypic leukemia10.4
43von willebrand's disease10.4
44retinitis10.4
45thpo-related essential thrombocythemia10.4
46erythrocytosis, somatic10.4SH2B3, JAK2
47myelofibrosis with myeloid metaplasia, somatic10.4SH2B3, JAK2
48liver cirrhosis10.3MPL, IFNA2, THPO
49hemorrhagic disease10.3PPBP, PF4, THBD
50dengue shock syndrome10.3THBD

Graphical network of the top 20 diseases related to Essential Thrombocythemia:



Diseases related to essential thrombocythemia

Symptoms for Essential Thrombocythemia

About this section

Symptoms:

 47 (show all 17)
  • transient amaurosis/acute visual trouble
  • thoracic/chest pain
  • angor pectoris/myocardial infarction
  • arterial embolism/thrombosis
  • venous thrombosis/phlebitis/thrombophlebitis
  • acute ischemic syndrome
  • cerebral vascular anomalies
  • transient cerebral ischemia/stroke
  • paresthesia/dysesthesia/hypoesthesia/anesthesia/numbness
  • bone marrow anomalies
  • platelet disorders/thrombopathies
  • platelets shape anomalies
  • hemorrhage/hemorrhagic syndrome/excessive/long-lasting bleeding
  • splenomegaly
  • acute leukemia
  • myeloproliferative syndrome/chronic leukemia
  • myelodysplastic syndrome

HPO human phenotypes related to Essential Thrombocythemia:

(show all 13)
id Description Frequency HPO Source Accession
1 coronary artery disease hallmark (90%) HP:0001677
2 abnormality of thrombocytes hallmark (90%) HP:0001872
3 abnormality of coagulation hallmark (90%) HP:0001928
4 cerebral ischemia hallmark (90%) HP:0002637
5 paresthesia hallmark (90%) HP:0003401
6 thrombophlebitis hallmark (90%) HP:0004418
7 arterial thrombosis hallmark (90%) HP:0004420
8 abnormality of bone marrow cell morphology hallmark (90%) HP:0005561
9 amaurosis fugax hallmark (90%) HP:0100576
10 chest pain hallmark (90%) HP:0100749
11 splenomegaly typical (50%) HP:0001744
12 acute leukemia occasional (7.5%) HP:0002488
13 myelodysplasia occasional (7.5%) HP:0002863

Drugs & Therapeutics for Essential Thrombocythemia

About this section

Genetic Tests for Essential Thrombocythemia

About this section

Genetic tests related to Essential Thrombocythemia:

id Genetic test Affiliating Genes
1 Essential Thrombocythemia22

Anatomical Context for Essential Thrombocythemia

About this section

MalaCards organs/tissues related to Essential Thrombocythemia:

31
Bone, Bone marrow, Spleen, Myeloid, Endothelial, Neutrophil, Liver, Lung, Whole blood, Spinal cord, Skin, Testes, Monocytes, T cells

Animal Models for Essential Thrombocythemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Essential Thrombocythemia:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053809.3MPL, TP53, JAK2, CALR, KLF5, THBD
2MP:00053788.6TET2, THBD, MPL, TP53, TPO, JAK2
3MP:00053848.5PPBP, TET2, THBD, SH2B3, MPL, TP53
4MP:00053878.3THBD, THPO, TET2, PPBP, SH2B3, MPL
5MP:00053978.2ALOX12, PPBP, TET2, THPO, THBD, SH2B3
6MP:00053768.2TP53, MPL, THBD, PPBP, TPO, PF4

Publications for Essential Thrombocythemia

About this section

Articles related to Essential Thrombocythemia:

(show top 50)    (show all 635)
idTitleAuthorsYear
1
CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation. (25838280)
2015
2
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. (25801912)
2015
3
Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia. (25132652)
2015
4
Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia. (25332611)
2014
5
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. (25037629)
2014
6
Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia. (25160063)
2014
7
Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France. (24118452)
2013
8
The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment. (23647225)
2013
9
Combination therapy of hydroxycarbamide with anagrelide inpatients with essential thrombocythemia in the evaluation ofXagrid(R): efficacy and long-term safety study. (24334294)
2013
10
The relationship of the active and latent forms of TGF-I^1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis. (22200991)
2012
11
Bilateral vertebral artery dissection and essential thrombocythemia with JAK2 mutation. (22677324)
2012
12
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. (22700720)
2012
13
Acral ischemia as a presenting manifestation of essential thrombocythemia. (21858443)
2011
14
Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets. (20113333)
2010
15
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. (19887674)
2010
16
The role of the Platelet Function Analyzer (PFA)-100 and platelet aggregometry in the differentiation of essential thrombocythemia from reactive thrombocytosis. (19664802)
2010
17
Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia. (20146031)
2010
18
Essential thrombocythemia with deleted 5q--a genetic and morphologic hybrid? (20633767)
2010
19
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. (19235016)
2009
20
JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. (19616600)
2009
21
Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia. (19093167)
2009
22
JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis. (19707158)
2009
23
Blast phase of essential thrombocythemia: A single center study. (19691103)
2009
24
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. (19364963)
2009
25
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. (18587010)
2008
26
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. (18268279)
2008
27
Association of inv(3)(q21q26) with essential thrombocythemia in transformation. (18617063)
2008
28
The V617F JAK2 mutation and the increase in platelet CD36 in essential thrombocythemia are unrelated events. (17573918)
2007
29
A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. (17361221)
2007
30
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. (17317589)
2007
31
Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis. (17852711)
2007
32
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. (17229651)
2007
33
Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. (17519959)
2007
34
Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. (16563815)
2006
35
Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. (16471068)
2006
36
Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia. (18386616)
2006
37
The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. (16810614)
2006
38
The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). (16926301)
2006
39
Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia. (15390356)
2005
40
Bone metabolism during interferon-alpha treatment of essential thrombocythemia. (15030122)
2004
41
Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia. (15048058)
2004
42
The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. (13679323)
2003
43
Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. (11978937)
2002
44
Historical perspective on the treatment of essential thrombocythemia and polycythemia vera. (9930553)
1999
45
Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia. (9517515)
1998
46
Clonality analysis of hematopoiesis and thrombopoietin levels in patients with essential thrombocythemia. (9669688)
1998
47
A possible role for thrombopoietin and its receptor c-mpl in the pathobiology of essential thrombocythemia. (9387200)
1997
48
Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. (8978285)
1997
49
Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. (8883266)
1996
50
Essential thrombocythemia developing into refractory anemia and complicated by acute myeloid leukemia. (1286233)
1992

Variations for Essential Thrombocythemia

About this section

Clinvar genetic disease variations for Essential Thrombocythemia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1MPLNM_005373.2(MPL): c.117G> T (p.Lys39Asn)single nucleotide variantrisk factorrs17292650GRCh37Chr 1, 43803807: 43803807
2MPLNM_005373.2(MPL): c.1514G> A (p.Ser505Asn)single nucleotide variantPathogenicrs121913614GRCh37Chr 1, 43814979: 43814979
3JAK2NM_004972.3(JAK2): c.1849G> T (p.Val617Phe)single nucleotide variantPathogenic, risk factorrs77375493GRCh37Chr 9, 5073770: 5073770
4JAK2NM_004972.3(JAK2): c.1849G> A (p.Val617Ile)single nucleotide variantPathogenicrs77375493GRCh37Chr 9, 5073770: 5073770
5SH2B3NM_005475.2(SH2B3): c.622G> C (p.Glu208Gln)single nucleotide variantPathogenicrs202080221GRCh37Chr 12, 111856571: 111856571
6THPOTHPO, IVS3, G-C, +1single nucleotide variantPathogenic
7THPOTHPO, 1-BP DEL, 3252GdeletionPathogenic
8THPOTHPO, 516G-Tsingle nucleotide variantPathogenic
9CALRNM_004343.3(CALR): c.1092_1143del52 (p.Leu367Thrfs)deletionPathogenicGRCh37Chr 19, 13054565: 13054616

Expression for genes affiliated with Essential Thrombocythemia

About this section
Search GEO for disease gene expression data for Essential Thrombocythemia.

Pathways for genes affiliated with Essential Thrombocythemia

About this section

Pathways related to Essential Thrombocythemia according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
IL-9 Signaling Pathway36
Development Thrombopoietin regulated cell processes58
IL-7 Signaling Pathway36
Immune response IL 9 signaling pathway58
10.0JAK2, MPL, THPO
2
Show member pathways
Development Thrombopoetin signaling via JAK STAT pathway58
10.0MPL, JAK2, THPO
3
Show member pathways
Type III interferon signaling36
9.8MPL, TPO, JAK2, IFNA2
49.7IFNA2, TP53, SH2B3, JAK2
5
Show member pathways
9.7THBD, PF4, CD177
6
Show member pathways
9.3TP53, PF4, PPBP, JAK2, THPO
7
Show member pathways
9.3JAK2, TP53, MPL, THPO, PPBP, IFNA2
8
Show member pathways
8.9PPBP, MPL, TP53, TPO, PF4, JAK2
9
Show member pathways
8.3MPL, PPBP, THPO, THBD, SH2B3, TP53

Compounds for genes affiliated with Essential Thrombocythemia

About this section

Compounds related to Essential Thrombocythemia according to GeneCards Suite gene sharing:

(show top 50)    (show all 112)
idCompoundScoreTop Affiliating Genes
1megapoietin4310.1MPL, THPO
2anagrelide43 1211.0THPO, MPL, PF4, JAK2, IFNA2
311-dehydrothromboxane b2439.9THBD, PPBP, PF4
4vitamin-e439.8THBD, IFNA2, JAK2, SULT1A3
5polyethylene glycol439.8THPO, PF4, THBD, MPL, IFNA2
6iloprost59 28 43 1212.8PPBP, THBD, PF4, THPO
7agar439.8MPL, JAK2, IFNA2, PF4, THPO
86-ketoprostaglandin f1alpha439.8PPBP, PF4, THBD
9histidine439.8TPO, THPO, CALR, MPL, SULT1A3, IFNA2
105fluorouracil439.8TP53, IFNA2, PF4, THPO, MPL
11thromboxane a243 2410.7PF4, ALOX12, PPBP, THPO
12iron43 2410.7IFNA2, CALR, ALOX12, TPO, MPL, THPO
13txb2439.7ALOX12, PF4, THBD, PPBP
14ptca439.6PF4, THBD, PPBP
15indomethacin43 28 59 1212.6IFNA2, ALOX12, PF4, THPO, JAK2
16quinacrine43 1210.6PPBP, PF4, ALOX12
17hydroxyurea43 49 1211.6JAK2, THPO, TP53, PPBP, PF4, IFNA2
18lysine439.6PF4, MPL, THPO, IFNA2, CALR, TPO
1912-o-tetradecanoylphorbol 13-acetate439.5IFNA2, ALOX12, TPO, JAK2, PF4
20prostacyclin439.5PF4, ALOX12, THPO, PPBP, THBD
21polysaccharide439.5PF4, THPO, TPO, THBD, CALR
22epinephrine43 24 1211.5IFNA2, JAK2, PF4, SULT1A3, THPO, PPBP
23h2o2439.5TPO, JAK2, THPO, CALR, THBD, ALOX12
24thromboxane43 2410.5PPBP, THBD, ALOX12, PF4, MPL, THPO
25aspartate439.5THBD, TPO, SULT1A3, JAK2, IFNA2, ALOX12
26histamine43 28 2411.4IFNA2, PF4, CALR, THBD, PPBP, THPO
27arachidonic acid43 28 24 1212.4PF4, THPO, PPBP, JAK2, IFNA2, ALOX12
28fibrinogen439.4SULT1A3, TPO, THBD, THPO, PPBP, PF4
29agarose439.4THBD, IFNA2, THPO, IGH, PPBP, TPO
30thymidine43 2410.3PF4, JAK2, IFNA2, ALOX12, THPO, PPBP
31heparin43 28 24 1212.3THBD, SULT1A3, PF4, PPBP, THPO, CALR
32creatinine439.3PPBP, THPO, THBD, TPO, SULT1A3, PF4
33retinoic acid43 2410.3THBD, THPO, IFNA2, TP53, TPO, JAK2
34dexamethasone43 49 28 1212.3THBD, CALR, JAK2, THPO, SULT1A3, ALOX12
35steroid439.2SULT1A3, JAK2, THPO, CALR, IFNA2, THBD
36genistein43 28 59 2 24 1214.2THPO, JAK2, TPO, SULT1A3, ALOX12
37estrogen439.2JAK2, TP53, SULT1A3, THBD, THPO, IFNA2
38oligonucleotide439.2CALR, TP53, TPO, THPO, SULT1A3, THBD
39nitric oxide43 24 1211.2CALR, JAK2, SULT1A3, THBD, THPO, PPBP
40oxygen43 2410.1ALOX12, THPO, IFNA2, CALR, JAK2, TPO
41aspirin43 49 28 2412.1PPBP, THBD, ALOX12, JAK2, PF4, SULT1A3
42atp43 2810.0PPBP, THPO, THBD, PF4, JAK2, ALOX12
43glucose439.0CALR, PPBP, THPO, THBD, PF4, JAK2
44cholesterol43 28 24 1212.0SULT1A3, TPO, THBD, PPBP, JAK2, PF4
45adp43 28 2411.0PF4, JAK2, STK16, MPL, THBD, THPO
46vegf438.9PPBP, THPO, JAK2, THBD, MPL, TP53
47alanine438.8IFNA2, KLF5, JAK2, PF4, MPL, THPO
48lipid438.8SULT1A3, PF4, JAK2, IFNA2, ALOX12, THBD
49cysteine438.7IFNA2, JAK2, CALR, PF4, TPO, PPBP
50tyrosine438.1THPO, PPBP, ABT1, THBD, SH2B3, MPL

GO Terms for genes affiliated with Essential Thrombocythemia

About this section

Cellular components related to Essential Thrombocythemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular spaceGO:00056158.8CALR, IFNA2, PF4, TPO, THBD, THPO

Biological processes related to Essential Thrombocythemia according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1myeloid cell differentiationGO:003009910.1THPO, TET2
2embryonic hemopoiesisGO:003516210.1TPO, SH2B3
3response to X-rayGO:001016510.1TP53, THBD
4platelet activationGO:00301689.6PPBP, THPO, MPL, PF4
5positive regulation of cell proliferationGO:00082849.6JAK2, CALR, ALOX12, KLF5
6positive regulation of gene expressionGO:00106289.5ALOX12, CALR, PF4
7blood coagulationGO:00075968.5CD177, PPBP, THPO, THBD, SH2B3, MPL

Molecular functions related to Essential Thrombocythemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1DNA bindingGO:00036779.2TET2, TP53, POLRMT, CALR, KLF5, ABT1
2protein bindingGO:00055157.5KLF5, ABT1, TET2, THBD, SH2B3, TP53

Products for genes affiliated with Essential Thrombocythemia

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Essential Thrombocythemia

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet